{"id":17541,"date":"2022-06-06T17:33:07","date_gmt":"2022-06-06T12:03:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17541"},"modified":"2024-09-18T13:24:43","modified_gmt":"2024-09-18T07:54:43","slug":"epidiolex-vs-fintepla","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","title":{"rendered":"Epidiolex vs Fintepla:  Fight in Rare Epilepsies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0be124ad364\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0be124ad364\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Better_Efficacy_Epidiolex_or_Fintepla\" >Better Efficacy: Epidiolex or Fintepla?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Why_Epidiolex_is_leading\" >Why Epidiolex is leading?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Expansion_to_other_Indications\" >Expansion to other Indications<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#European_Market_Challenges\" >European Market Challenges<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Is_Fintepla_too_late_in_the_market_or_will_it_be_able_to_catch_up_to_the_Epidiolex\" >Is Fintepla too late in the market or will it be able to catch up to the Epidiolex?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Epidiolex (Jazz Pharma) and Fintepla (Zogenix &#8211; Acquired by UCB) are locking horns in the rare <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">developmental and epileptic encephalopathies (DEE) market<\/a> with Epidiolex currently leading in terms of sale. Epidiolex has clocked over <strong>USD 650 million<\/strong> in sales and on the other hand Fintepla is far behind at just <strong>USD 74.7 million<\/strong> in 2021.&nbsp; The unexpectedly strong uptake and high sales of Epidiolex is mainly due to the first-mover advantage of a novel class in this space which only had Antiepileptic Drugs (AEDs) used in combination mainly. Moreover, Epidiolex received approval for both Lennox Gastaut Syndrome (LGS) and Dravet Syndrome together in mid-2018 whereas Fintepla\u2019s first approved indication was Dravet Syndrome in mid-2020, which gave Epidiolex almost 2 years in the US market alone without any competition.<\/p>\n\n\n\n<p>We expect the scenario of Fintepla to take a positive turn going forward as recently it gained FDA approval for Lennox Gastaut Syndrome (LGS) in <strong>March 2022<\/strong>. The Fintepla FDA approval in the Lennox Gastaut Syndrome can be a game-changer for UCB, the reason lies in the addressable patient pool. In the US there are approximately <strong>20k<\/strong> patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">Dravet syndrome<\/a> but the <a href=\"https:\/\/www.delveinsight.com\/report-store\/lennox-gastaut-syndrome-epidemiology-forecast\">Lennox Gastaut Syndrome patient pool<\/a> is more than double at approximately <strong>45-50k<\/strong> patients.<\/p>\n\n\n\n<p>Key <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">developmental and epileptic encephalopathy companies<\/a> with their lead products such as <strong>Epygenix (EPX-100), (EPX-200) (Lorcaserin) and (EPX-300), Neurocrine Biosciences (NBI-921352) (XEN901Xenon Pharmaceuticals (XEN 496), Takeda (Soticlestat) (OV935\/TAK-935), Praxis Precision Medicines (PRAX-562)<\/strong>, and others are working on developing a new developmental and epileptic encephalopathies treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market-1024x473.png\" alt=\"Key Companies in the Developmental and Epileptic Encephalopathy Market\" class=\"wp-image-17548\" width=\"558\" height=\"257\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market-1024x473.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market-300x139.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market-150x69.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market-768x355.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171018\/Key-Companies-in-the-Developmental-and-Epileptic-Encephalopathy-Market.png 1093w\" sizes=\"(max-width: 558px) 100vw, 558px\" \/><figcaption><strong>Pharma Leaders in the Developmental and Epileptic Encephalopathy Market<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Better_Efficacy_Epidiolex_or_Fintepla\"><\/span><strong>Better Efficacy: Epidiolex or Fintepla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Out of Epidiolex and Fintepla, the overall efficacy and safety of both drugs are significant, however, when comparing their efficiency against each other in Dravet syndrome, the drug response rate of Fintepla was four times compared to placebo. In contrast, Epidiolex reduced the seizure frequency by three times compared to placebo. For Lennox Gastaut Syndrome, the drug response rate of Fintepla was three times compared to placebo, whereas <a href=\"https:\/\/www.delveinsight.com\/report-store\/epidiolex-cannabidiol-drug-insight-market-forecast\">Epidiolex<\/a> reduced the seizure frequency by two times compared to placebo. Also, the efficacy numbers of Fintepla were lower in Lennox Gastaut Syndrome compared to a 60%+ reduction in Dravet syndrome. Thus, Fintepla beats Epidiolex in terms of efficacy. In fact, we believe that Fintepla\u2019s efficacy in Dravet patients is much higher when compared to those suffering from Lennox Gastaut Syndrome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Epidiolex_is_leading\"><\/span><strong>Why Epidiolex is leading?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Epidiolex FDA approval for Dravet syndrome and Lennox Gastaut Syndrome was in 2018, and TSC-associated epilepsy was in 2020. Being a CBD, there were doubts regarding the success of Epidiolex, but Jazz made full use of Epidiolex\u2019s first-mover advantage and gained significant market share in the three years beating the estimates and crossing half a billion-dollar mark in sales in 2020.\u00a0 On the other hand, Fintepla FDA approval was in 2020 for Dravet syndrome and in March 2022 for Lennox Gastaut Syndrome. Because Fintepla was launched by Zogenix in July 2020, the initial Fintepla launch period has been affected by the pandemic. Furthermore, the drug is available through a restricted distribution program, which also impacted the sales as the prescribers have to complete REMS certification prior to prescribing Fintepla. Another reason Epidiolex has done well is the approval in one extra condition i.e. TSC associated seizures, which also has approximately 50k patients in the US and this significantly increases the total addressable pool to almost 120k patients in the US for Epidiolex compared to Fintepla, which was only targeting <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-pipeline-insight\">Dravet syndrome<\/a> (20k patients in the US) prior to March 2022. Thus, Epidiolex had a six times bigger pool to target which translated to higher sales but since Fintepla is approved for Lennox Gastaut Syndrome the competition has arrived.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-71934476-19d8-48be-b9b8-2a473dcb4fd6\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 336 400\" width=\"336\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-03otf3t-1253-\"><rect fill=\"none\" height=\"233\" width=\"252\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-03otf3t-1257-\"><rect fill=\"none\" height=\"233\" width=\"252\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-03otf3t-1261-\"><rect fill=\"none\" height=\"233\" width=\"252\" x=\"74\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"336\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"233\" width=\"252\" x=\"74\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 116.5 92 L 116.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 199.5 92 L 199.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 282.5 92 L 282.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 74 325.5 L 326 325.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74 267.5 L 326 267.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74 209.5 L 326 209.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74 150.5 L 326 150.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74 91.5 L 326 91.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"233\" width=\"252\" x=\"74\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-tick\" d=\"M 116.5 325 L 116.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-tick\" d=\"M 199.5 325 L 199.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-tick\" d=\"M 282.5 325 L 282.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-axis-line\" d=\"M 74 325.5 L 326 325.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.0888671875 208.5)\" x=\"26.0888671875\" y=\"208.5\">Revenue in USD Million<\/text><path class=\"highcharts-axis-line\" d=\"M 74 92 L 74 325\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" aria-label=\"Fintepla, bar series 1 of 2 with 3 bars.\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-03otf3t-1257-)\" data-z-index=\"0.1\" opacity=\"1\" role=\"region\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(74,92) scale(1 1)\"><rect aria-label=\"x, 2019, 0. Fintepla.\" class=\"highcharts-point highcharts-color-0\" fill=\"#90caf9\" height=\"0\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"20.5\" y=\"233.5\"><\/rect><rect aria-label=\"x, 2020, 9.6. Fintepla.\" class=\"highcharts-point highcharts-color-0\" fill=\"#90caf9\" height=\"3\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"103.5\" y=\"230.5\"><\/rect><rect aria-label=\"x, 2021, 74.7. Fintepla.\" class=\"highcharts-point highcharts-color-0\" fill=\"#90caf9\" height=\"22\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"186.5\" y=\"211.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(74,92) scale(1 1)\"><\/g><g aria-hidden=\"false\" aria-label=\"Epidiolex, bar series 2 of 2 with 3 bars.\" class=\"highcharts-series highcharts-series-1 highcharts-column-series highcharts-color-1\" clip-path=\"url(#highcharts-03otf3t-1257-)\" data-z-index=\"0.1\" opacity=\"1\" role=\"region\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(74,92) scale(1 1)\"><rect aria-label=\"x, 2019, 296.4. Epidiolex.\" class=\"highcharts-point highcharts-color-1\" fill=\"#2979ff\" height=\"86\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"45.5\" y=\"147.5\"><\/rect><rect aria-label=\"x, 2020, 510.5. Epidiolex.\" class=\"highcharts-point highcharts-color-1\" fill=\"#2979ff\" height=\"149\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"127.5\" y=\"84.5\"><\/rect><rect aria-label=\"x, 2021, 658.3. Epidiolex.\" class=\"highcharts-point highcharts-color-1\" fill=\"#2979ff\" height=\"192\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"20\" x=\"210.5\" y=\"41.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-1 highcharts-column-series highcharts-color-1\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(74,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"168\" y=\"24\">Developmental and Epileptic<tspan dy=\"21\" x=\"168\">\u200b<\/tspan>Encephalopathy Market<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"168\" y=\"73\">Epidiolex vs Fintepla Sales<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(74,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(21,210)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">0<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>0<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(99,207)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">9.6<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>9.6<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(178,188)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">74.7<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>74.7<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-1 highcharts-column-series highcharts-color-1\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(74,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(34,124)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">296.4<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>296.4<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(116,61)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">510.5<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>510.5<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(199,18)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">658.3<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>658.3<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-legend highcharts-no-tooltip\" data-z-index=\"7\" transform=\"translate(77,359)\"><rect class=\"highcharts-legend-box\" fill=\"none\" height=\"26\" rx=\"0\" ry=\"0\" width=\"182\" x=\"0\" y=\"0\"><\/rect><g data-z-index=\"1\"><g><g class=\"highcharts-legend-item highcharts-column-series highcharts-color-0 highcharts-series-0\" data-z-index=\"1\" transform=\"translate(8,3)\"><text data-z-index=\"2\" style=\"color: rgb(51, 51, 51); cursor: pointer; font-size: 12px; font-weight: bold; fill: rgb(51, 51, 51);\" text-anchor=\"start\" x=\"21\" y=\"15\">Fintepla<\/text><rect class=\"highcharts-point\" data-z-index=\"3\" fill=\"#90caf9\" height=\"12\" rx=\"6\" ry=\"6\" width=\"12\" x=\"2\" y=\"4\"><\/rect><\/g><g class=\"highcharts-legend-item highcharts-column-series highcharts-color-1 highcharts-series-1\" data-z-index=\"1\" transform=\"translate(97.544921875,3)\"><text data-z-index=\"2\" style=\"color: rgb(51, 51, 51); cursor: pointer; font-size: 12px; font-weight: bold; fill: rgb(51, 51, 51);\" text-anchor=\"start\" x=\"21\" y=\"15\">Epidiolex<\/text><rect class=\"highcharts-point\" data-z-index=\"3\" fill=\"#2979ff\" height=\"12\" rx=\"6\" ry=\"6\" width=\"12\" x=\"2\" y=\"4\"><\/rect><\/g><\/g><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"117.10526315789\" y=\"344\">2019<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"200\" y=\"344\">2020<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"282.8947368421\" y=\"344\">2021<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"59\" y=\"329\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"59\" y=\"271\">200<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"59\" y=\"213\">400<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"59\" y=\"154\">600<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"59\" y=\"96\">800<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Developmental and Epileptic Encephalopathy Market\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"326\" y=\"395\">Developmental and Epileptic Encephalopathy Market<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-03otf3t-1261-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Developmental and Epileptic Encephalopathy Market\"},\"subtitle\":{\"text\":\"Epidiolex vs Fintepla Sales\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Fintepla\"},{\"name\":\"Epidiolex\"}],\"data\":{\"csv\":\"\\\"null\\\";\\\"Fintepla\\\";\\\"Epidiolex\\\"\\n2019;0;296.4\\n2020;9.6;510.5\\n2021;74.7;658.3\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Revenue in USD Million\"}}],\"colors\":[\"#90caf9\",\"#2979ff\",\"#90ed7d\",\"#f7a35c\",\"#8085e9\",\"#01579b\",\"#e4d354\",\"#2b908f\",\"#f45b5b\",\"#91e8e1\"],\"credits\":{\"text\":\"Developmental and Epileptic Encephalopathy Market\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-71934476-19d8-48be-b9b8-2a473dcb4fd6\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expansion_to_other_Indications\"><\/span><strong>Expansion to other Indications<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Apart from Lennox Gastaut Syndrome and Dravet syndrome, UCB Pharma is advancing Fintepla for seizures due to <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\">CDKL5 (cyclin-dependent kinase-like 5) deficiency<\/a>. There are roughly<strong> 6,000<\/strong> of these patients in the US, which makes it a significant potential market opportunity but recently Marinus Pharma\u2019s <strong>Ztalmy<\/strong> gained an FDA nod for the same indication. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-epidemiology-forecast\">CDKL5 deficiency pool<\/a> is quite small when compared to TSC and we expect <strong>Ztalmy<\/strong> to have a first-mover advantage in this market. Moreover, Fintepla is yet to prove its mettle in CDKL5 deficiency but Epidiolex has already been approved in TSC-associated seizures and this is a major differentiator between the two drugs and can be seen clearly in terms of sale. Furthermore, Jazz is also targeting the fourth indication for Epidiolex and expects to initiate a Phase III pivotal Epidiolex trial for Epilepsy with Myoclonic-Atonic Seizures (EMAS) or <a href=\"https:\/\/www.delveinsight.com\/report-store\/doose-syndrome-market\">Doose syndrome <\/a>in 2022.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"European_Market_Challenges\"><\/span><strong>European Market Challenges<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The European market seems to be challenging for both Epidiolex and Fintepla. Although Epidiolex (Epidyolex in Europe) is now commercially available and fully reimbursed in four of the five key <strong>European markets: the United Kingdom, Germany, Italy, and Spain<\/strong>, with an anticipated launch in France in 2022. Moreover, the company has made significant progress on its European rollout with launches in Spain and Italy in 3Q21 but it took them quite to reach the market. Similarly, Fintepla is also facing challenges and is currently commercially available in <strong>Germany<\/strong> and <strong>France <\/strong>and is under NICE technology appraisal in the UK but<strong> 2.2mg\/ml<\/strong> oral solution of Fintepla is available in the UK from December 2021.<\/p>\n\n\n\n<p>When it comes to Japan Zogenix has filed a J-NDA in collaboration with Nippon Shinyaku. While Epidiolex has only gained approval for conducting the clinical trials.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-8a44e422-adf4-4f6d-a523-cc6f249473b4\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 348 400\" width=\"348\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-grsqxhi-395-\"><rect fill=\"none\" height=\"314\" width=\"328\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-grsqxhi-397-\"><rect fill=\"none\" height=\"314\" width=\"328\" x=\"10\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"348\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"314\" width=\"328\" x=\"10\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"314\" width=\"328\" x=\"10\" y=\"71\"><\/rect><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-pie-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><path aria-label=\"Fintepla, 19. Percent share of drugs.\" class=\"highcharts-point highcharts-color-0\" d=\"M 165.4918530718522 111.50000082965548 A 40 40 0 0 1 202.67618474768494 136.7375040184257 L 187.80571084861097 142.64250241105543 A 24 24 0 0 0 165.49511184311132 127.5000004977933 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Anti-epileptic drugs, 5. Percent share of drugs.\" class=\"highcharts-point highcharts-color-1\" d=\"M 202.6909286531153 136.77468757822473 A 40 40 0 0 1 205.4181079582092 148.94174726878762 L 189.45086477492552 149.96504836127258 A 24 24 0 0 0 187.81455719186917 142.66481254693485 Z\" fill=\"#434348\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Epidiolex, 21. Percent share of drugs.\" class=\"highcharts-point highcharts-color-2\" d=\"M 205.42064625146173 148.98166664921908 A 40 40 0 0 1 177.88491252228096 189.5343784202588 L 172.93094751336858 174.3206270521553 A 24 24 0 0 0 189.45238775087702 149.98899998953144 Z\" fill=\"#90ed7d\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Everolimus, 1. Percent share of drugs.\" class=\"highcharts-point highcharts-color-3\" d=\"M 177.84687195774404 189.5467443135293 A 40 40 0 0 1 175.50449536841006 190.22867248465226 L 171.50269722104605 174.73720349079136 A 24 24 0 0 0 172.90812317464642 174.3280465881176 Z\" fill=\"#f7a35c\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Ztalmy, 4. Percent share of drugs.\" class=\"highcharts-point highcharts-color-4\" d=\"M 175.46576170013293 190.23865761401862 A 40 40 0 0 1 165.53185306842934 191.4999873172734 L 165.5191118410576 175.49999239036404 A 24 24 0 0 0 171.47945702007976 174.74319456841118 Z\" fill=\"#8085e9\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Soticlestat, 12. Percent share of drugs.\" class=\"highcharts-point highcharts-color-5\" d=\"M 165.4918530718522 191.49999917034452 A 40 40 0 0 1 138.14082599867874 180.68005479716282 L 149.08449559920723 169.0080328782977 A 24 24 0 0 0 165.49511184311132 175.49999950220672 Z\" fill=\"#f15c80\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"Other potential therapies, 38. Percent share of drugs.\" class=\"highcharts-point highcharts-color-6\" d=\"M 138.11165962833076 180.6526810376952 A 40 40 0 0 1 165.44444080247715 111.50003858532398 L 165.46666448148628 127.50002315119438 A 24 24 0 0 0 149.06699577699845 168.99160862261712 Z\" fill=\"#e4d354\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-pie-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"174\" y=\"24\">Epilepsy Drugs<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"174\" y=\"52\">Developmental and Epileptic Encephalopathy<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-pie-series\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><path class=\"highcharts-data-label-connector highcharts-color-0\" d=\"M 209.84583644964914 93.60435980078067 C 204.84583644964914 93.60435980078067 194.72833564831075 108.4918101377228 191.35583538119798 113.45429358337016 L 187.9833351140852 118.41677702901752\" fill=\"none\" stroke=\"#7cb5ec\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-1\" d=\"M 238.81417333571233 136.229973102242 C 233.81417333571233 136.229973102242 216.24767162081488 140.1565514473798 210.3921710491824 141.46541089575905 L 204.5366704775499 142.7742703441383\" fill=\"none\" stroke=\"#434348\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-2\" d=\"M 228.39564019921934 190.8458364496491 C 223.39564019921934 190.8458364496491 208.50818986227722 180.72833564831075 203.54570641662986 177.35583538119798 L 198.5832229709825 173.9833351140852\" fill=\"none\" stroke=\"#90ed7d\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-3\" d=\"M 190.02937742274608 218.720557997386 C 185.02937742274608 218.720557997386 180.00753751403994 201.43527165520106 178.33359087780457 195.6735095411394 L 176.6596442415692 189.91174742707773\" fill=\"none\" stroke=\"#f7a35c\" stroke-width=\"1\" visibility=\"hidden\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-4\" d=\"M 179.27332634950145 220.94802909201343 C 174.27332634950145 220.94802909201343 172.01732814534384 203.08996446835283 171.265328743958 197.13727626046597 L 170.51332934257218 191.1845880525791\" fill=\"none\" stroke=\"#8085e9\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-5\" d=\"M 134.73128131207258 216.5843540121776 C 139.73128131207258 216.5843540121776 146.3575232603968 199.84837726618906 148.56627057650485 194.26971835085956 L 150.7750178926129 188.69105943553006\" fill=\"none\" stroke=\"#f15c80\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-6\" d=\"M 95.41564598782239 125.7312813120726 C 100.41564598782239 125.7312813120726 117.15162273381091 132.3575232603968 122.73028164914042 134.56627057650485 L 128.30894056446994 136.7750178926129\" fill=\"none\" stroke=\"#e4d354\" stroke-width=\"1\"><\/path><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(215,84)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Fintepla<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Fintepla<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(244,126)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\"><title><\/title>Anti-epilepti\u2026<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan><title><\/title>Anti-epilepti\u2026<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-2\" data-z-index=\"1\" transform=\"translate(233,181)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Epidiolex<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Epidiolex<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-3\" data-z-index=\"1\" transform=\"translate(195,209)\" visibility=\"hidden\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Everolimus<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Everolimus<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-4\" data-z-index=\"1\" transform=\"translate(184,211)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Ztalmy<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Ztalmy<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-5\" data-z-index=\"1\" transform=\"translate(63,207)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Soticlestat<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Soticlestat<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-6\" data-z-index=\"1\" transform=\"translate(-10,116)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\"><title><\/title>Other potentia\u2026<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan><title><\/title>Other potentia\u2026<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-legend highcharts-no-tooltip\" data-z-index=\"7\"><rect class=\"highcharts-legend-box\" fill=\"none\" height=\"8\" rx=\"0\" ry=\"0\" visibility=\"hidden\" width=\"8\" x=\"0\" y=\"0\"><\/rect><g data-z-index=\"1\"><g><\/g><\/g><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Developmental and Epileptic Encephalopathy Market\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"338\" y=\"395\">Developmental and Epileptic Encephalopathy Market<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-grsqxhi-397-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Epilepsy Drugs\"},\"subtitle\":{\"text\":\"Developmental and Epileptic Encephalopathy\"},\"exporting\":{},\"chart\":{\"type\":\"pie\",\"polar\":false},\"plotOptions\":{\"pie\":{\"allowPointSelect\":true,\"cursor\":true,\"innerSize\":\"60%\",\"dataLabels\":{\"enabled\":true}},\"series\":{\"animation\":false}},\"series\":[{\"name\":\"Percent share of drugs\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Drug medications\\\";\\\"Percent share of drugs\\\"\\n\\\"Fintepla\\\";19\\n\\\"Anti-epileptic drugs\\\";5\\n\\\"Epidiolex\\\";21\\n\\\"Everolimus\\\";1\\n\\\"Ztalmy\\\";4\\n\\\"Soticlestat\\\";12\\n\\\"Other potential therapies\\\";38\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"\"}}],\"credits\":{\"text\":\"Developmental and Epileptic Encephalopathy Market\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-8a44e422-adf4-4f6d-a523-cc6f249473b4\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-is-fintepla-too-late-in-the-market-or-will-it-be-able-to-catch-up-to-the-epidiolex\"><span class=\"ez-toc-section\" id=\"Is_Fintepla_too_late_in_the_market_or_will_it_be_able_to_catch_up_to_the_Epidiolex\"><\/span><strong>Is Fintepla too late in the market or will it be able to catch up to the Epidiolex?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As far as catching up is considered, Fintepla can do that based on the fast uptake it has shown coupled with the better efficacy. The orphan drug exclusivity of Epidiolex will expire in 2025 for Lennox Gastaut Syndrome and Dravet syndrome and in 2027 for TSC-associated seizures, at the same time, Epidiolex will reach its peak as well, whereas Fintepla will continue to gain the <a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight\">epilepsy market share<\/a> but will be behind Epidiolex even in 2032.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-1024x256.png\" alt=\"\" class=\"wp-image-17543\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06165343\/Developmental-and-Epileptic-Encephalopathy-Market.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1654514197845\"><strong class=\"schema-faq-question\"><strong>What is Developmental Epileptic Encephalopathy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514220903\"><strong class=\"schema-faq-question\"><strong>How is Epileptic Encephalopathy diagnosis done?<\/strong><\/strong> <p class=\"schema-faq-answer\">The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514240789\"><strong class=\"schema-faq-question\"><strong>Which companies are working in the Developmental Epileptic Encephalopathy market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading pharma companies such as Epygenix, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda\/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, BioPharm Solutions, and others are working on developing a novel approach to treating Developmental Epileptic Encephalopathy.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514261421\"><strong class=\"schema-faq-question\"><strong>Is Developmental and Epileptic Encephalopathy fatal?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Epidiolex (Jazz Pharma) and Fintepla (Zogenix &#8211; Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74.7 million in 2021.&nbsp; [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17549,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22276,22275,22277,2885,1494,2958],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-17541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dee-market","tag-dee-therapies","tag-dee-treatment","tag-epidiolex","tag-epilepsy","tag-fintepla-zogenix","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Developmental and Epileptic Encephalopathy Market Therapies<\/title>\n<meta name=\"description\" content=\"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Developmental and Epileptic Encephalopathy Market Therapies\" \/>\n<meta property=\"og:description\" content=\"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-06T12:03:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:54:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Developmental and Epileptic Encephalopathy Market Therapies","description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","og_locale":"en_US","og_type":"article","og_title":"Developmental and Epileptic Encephalopathy Market Therapies","og_description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","og_url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-06-06T12:03:07+00:00","article_modified_time":"2024-09-18T07:54:43+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","name":"Developmental and Epileptic Encephalopathy Market Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","datePublished":"2022-06-06T12:03:07+00:00","dateModified":"2024-09-18T07:54:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","width":772,"height":482,"caption":"Epileptic Encephalopathy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845","name":"What is Developmental Epileptic Encephalopathy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903","name":"How is Epileptic Encephalopathy diagnosis done?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789","name":"Which companies are working in the Developmental Epileptic Encephalopathy market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading pharma companies such as Epygenix, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda\/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, BioPharm Solutions, and others are working on developing a novel approach to treating Developmental Epileptic Encephalopathy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421","name":"Is Developmental and Epileptic Encephalopathy fatal?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epidiolex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epilepsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fintepla (Zogenix)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DEE Market<\/span>","<span class=\"advgb-post-tax-term\">DEE Therapies<\/span>","<span class=\"advgb-post-tax-term\">DEE Treatment<\/span>","<span class=\"advgb-post-tax-term\">Epidiolex<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy<\/span>","<span class=\"advgb-post-tax-term\">Fintepla (Zogenix)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 6, 2022","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jun 6, 2022 5:33 pm","modified":"Updated on Sep 18, 2024 1:24 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17541"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541\/revisions"}],"predecessor-version":[{"id":29599,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541\/revisions\/29599"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17549"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17541"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17541"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}